Prometrium Cost in Indiana (2026): Pricing, Insurance, and Savings Options

Prescription access and medication affordability image for Prometrium Cost in Indiana (2026): Pricing, Insurance, and Savings Options

How Much Does Prometrium Cost in Indiana in 2026?

At a glance

  • Brand Prometrium list price / $180 per month (AbbVie)
  • Average Indiana cash-pay price / $45 per month at retail pharmacies
  • Compounded micronized progesterone / approximately $25 per month via 503A pharmacies
  • Indiana Medicaid coverage / not covered for HRT endometrial protection
  • Telehealth prescribing / legal and available statewide in Indiana
  • Dose form / oral capsule, typically 200 mg at bedtime
  • Standard schedule / once daily for 12 days per cycle or continuous
  • Manufacturer savings card / AbbVie copay program may reduce cost to $25-$35
  • Compounded availability / legal via licensed 503A pharmacies in Indiana
  • Generic micronized progesterone / available and typically priced near $45 per month

Indiana Retail Pricing for Prometrium in 2026

The average cash-pay price for a 30-day supply of Prometrium (micronized progesterone 200 mg capsules) at Indiana retail pharmacies is $45 per month in 2026. This figure represents the out-of-pocket cost without insurance or discount cards at chains including CVS, Walgreens, and Kroger Pharmacy locations across Indianapolis, Fort Wayne, Evansville, and other metro areas.

AbbVie's manufacturer list price remains $180 per month, but virtually no patient pays this amount. The gap between list and cash-pay pricing reflects pharmacy benefit manager negotiations and generic competition. Generic micronized progesterone capsules (bioequivalent to Prometrium per FDA Orange Book ratings) account for most dispensed prescriptions in Indiana.

Pricing varies by pharmacy location. Independent pharmacies in rural Indiana counties may charge $5-$15 more than urban chain locations due to lower prescription volume and different wholesale contracts. Patients filling at Costco or Amazon Pharmacy without insurance often see prices $5-$10 below the state average [1].

Indiana Medicaid Coverage Status

Indiana Medicaid does not cover Prometrium for endometrial protection in hormone replacement therapy. The Indiana Health Coverage Programs formulary lists micronized progesterone coverage only for type 2 diabetes-related indications, which effectively excludes the standard HRT use case.

This coverage gap affects women on the Healthy Indiana Plan (HIP) and traditional Medicaid who need progesterone as part of combined estrogen-progestogen therapy. The Endocrine Society's 2022 guidelines recommend micronized progesterone over synthetic progestins for endometrial protection based on superior cardiovascular and breast safety profiles demonstrated in the PEPI trial [2].

Women enrolled in Indiana Medicaid who require progesterone for HRT have three practical options: appeal for prior authorization citing medical necessity, pay cash ($45 per month average), or use a compounded alternative ($25 per month). Prior authorization appeals succeed inconsistently. The formulary restriction does not apply to progesterone prescribed for secondary amenorrhea, which remains a covered indication.

Compounded Micronized Progesterone in Indiana

Compounded micronized progesterone is legal and available in Indiana through licensed 503A compounding pharmacies. These pharmacies operate under individual patient prescriptions and must comply with Indiana Board of Pharmacy regulations and USP 795/800 standards.

The typical price for compounded micronized progesterone in Indiana is $25 per month. This represents a 44% savings compared to the $45 average cash-pay price for manufactured generic capsules. Several 503A pharmacies in Indianapolis, Carmel, and Fishers offer compounded progesterone in oral capsules, troches, and topical cream formulations.

Patients should verify their compounding pharmacy holds a current Indiana Board of Pharmacy license and sources USP-grade micronized progesterone powder. The FDA's 2020 guidance on compounded bioidentical hormones confirms that patient-specific compounding of progesterone is permissible under section 503A of the Federal Food, Drug, and Cosmetic Act, provided the pharmacy meets all applicable requirements.

One consideration: compounded formulations do not undergo the same bioequivalence testing as FDA-approved generics. The PEPI trial (N=875) specifically used oral micronized progesterone at 200 mg daily, and results may not directly extrapolate to non-oral routes or non-standard formulations [2].

Insurance Coverage Beyond Medicaid

Most commercial insurance plans available on the Indiana ACA marketplace and through employer-sponsored coverage include generic micronized progesterone on their formularies. Typical copays range from $10-$30 depending on the plan tier.

Plans from major Indiana insurers including Anthem Blue Cross Blue Shield, UnitedHealthcare, and CareSource generally place generic micronized progesterone on Tier 1 or Tier 2. Brand-name Prometrium, when specifically requested, usually falls on Tier 3 with copays of $50-$75.

The Women's Preventive Services Initiative guidelines support coverage of FDA-approved contraceptive and HRT medications without cost-sharing under the ACA preventive services mandate. However, progesterone prescribed specifically for endometrial protection in HRT (rather than contraception) may not qualify for zero cost-sharing in all plans. Patients should confirm with their specific insurer whether their indication triggers the preventive services benefit.

Indiana state employees covered under the State Personnel Department health plan have generic micronized progesterone covered at the Tier 1 copay ($15 in 2026). This applies to both Anthem and UnitedHealthcare options offered through the state employee program.

Telehealth Prescribing in Indiana

Indiana law permits telehealth prescribing of Prometrium and generic micronized progesterone statewide. No in-person visit is required before a provider writes this prescription. Indiana's telehealth parity law (IC 25-1-9.5) requires insurers to cover telehealth visits at the same rate as in-person encounters.

For patients outside metro Indianapolis, telehealth eliminates travel to endocrinology or gynecology specialists. Several telehealth platforms operating in Indiana, including HealthRX, can prescribe micronized progesterone after a virtual consultation and have it filled at the patient's local pharmacy or shipped via mail-order.

Prescriptions written via telehealth carry no pricing penalty at Indiana pharmacies. The same cash-pay and insurance rates apply regardless of whether the prescriber saw the patient virtually or in person. Mail-order options through telehealth platforms sometimes offer additional savings of $5-$10 per month compared to retail.

The AbbVie Savings Card Program

AbbVie (which acquired Solvay's progesterone portfolio) offers a manufacturer copay savings card for brand-name Prometrium. Eligible patients with commercial insurance can reduce their out-of-pocket cost to as low as $25 per fill.

Eligibility requirements for the savings card include: active commercial insurance (not Medicare, Medicaid, or Tricare), a valid prescription for brand-name Prometrium specifically, and U.S. residency. Indiana patients meeting these criteria can activate the card online or through their prescriber's office.

The savings card provides limited value for most Indiana patients because generic micronized progesterone already costs $45 per month at cash-pay prices. Unless a patient's insurance copay for brand Prometrium exceeds $45, the generic route without a savings card may still be cheaper than brand with the card. The math changes if the savings card reduces brand cost below the generic cash price, which occurs in some high-deductible plan scenarios.

Annual maximum benefit on the AbbVie savings card is typically $3,600 (equivalent to 12 months at $300 per month in manufacturer subsidy). The card resets annually and must be re-enrolled each calendar year.

Clinical Context: Why Micronized Progesterone Matters

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875, JAMA 1995) established oral micronized progesterone 200 mg as the preferred agent for endometrial protection during estrogen therapy. Women randomized to micronized progesterone had equivalent endometrial protection to medroxyprogesterone acetate (MPA) while preserving the HDL-cholesterol benefit of estrogen alone [2].

"Micronized progesterone provides endometrial protection comparable to MPA without attenuating the beneficial effects of estrogen on lipoproteins," the PEPI investigators reported in their primary analysis [2].

The 2022 North American Menopause Society position statement reinforces this preference, noting that "micronized progesterone and dydrogesterone have metabolic advantages over other progestogens and should be considered first-line options."

These clinical distinctions matter for Indiana patients navigating cost decisions. Switching from micronized progesterone to cheaper synthetic progestins (like MPA at $4 per month) saves money but potentially sacrifices cardiovascular and breast safety margins demonstrated across multiple observational studies [3].

Practical Cost Comparison Table

For a standard 200 mg daily regimen in Indiana (2026 pricing):

Brand Prometrium without insurance runs $180 per month at list price, though no major Indiana pharmacy charges this amount in practice. Generic micronized progesterone at retail averages $45 per month. With a GoodRx or RxSaver coupon, generic pricing drops to $30-$38 at most Indiana locations. Compounded micronized progesterone from 503A pharmacies costs approximately $25 per month. With commercial insurance (Tier 1-2), expect $10-$30 per month.

The lowest-cost legal option in Indiana remains compounded micronized progesterone at $25 per month, assuming the patient has access to a licensed 503A pharmacy and their prescriber is comfortable writing for a compounded product. For patients who prefer an FDA-approved formulation, generic capsules with a discount card represent the best value at $30-$38 per month.

How to Get the Lowest Price in Indiana

Step one: confirm your insurance formulary status. Call the number on your insurance card and ask whether "micronized progesterone 200 mg capsules" (not brand Prometrium) is covered and at which tier.

Step two: if uninsured or if your copay exceeds $40, check GoodRx, RxSaver, and Amazon Pharmacy pricing for your zip code. Prices vary by $10-$15 between Indiana pharmacies even within the same city.

Step three: if cost remains a barrier, ask your prescriber about compounded micronized progesterone from a licensed Indiana 503A pharmacy. Confirm the pharmacy uses USP-grade powder and follows current compounding standards.

Step four: for brand-name Prometrium specifically, check AbbVie's patient assistance program if your household income falls below 200% of the federal poverty level. The program provides free medication to qualifying uninsured or underinsured patients.

Indiana patients using telehealth platforms may also benefit from platform-negotiated pharmacy pricing that undercuts standard retail. Ask your telehealth provider whether their pharmacy network offers preferred pricing on progesterone.

Frequently asked questions

How much does Prometrium cost in Indiana?
Brand-name Prometrium lists at $180 per month, but the average cash-pay price for generic micronized progesterone at Indiana retail pharmacies is $45 per month in 2026. With discount cards, prices drop to $30-$38.
Does Indiana Medicaid cover Prometrium?
Indiana Medicaid does not cover Prometrium or generic micronized progesterone for HRT endometrial protection. Coverage exists only for type 2 diabetes-related indications. Patients on Medicaid pay cash ($45 average) or use compounded alternatives ($25 per month).
Is compounded micronized progesterone legal in Indiana?
Yes. Compounded micronized progesterone is legal in Indiana through licensed 503A compounding pharmacies operating under individual patient prescriptions. These pharmacies must comply with Indiana Board of Pharmacy regulations and USP compounding standards.
Can I get Prometrium via telehealth in Indiana?
Yes. Indiana law permits telehealth prescribing of micronized progesterone without requiring an in-person visit first. The prescription can be filled at any Indiana pharmacy or shipped via mail-order.
Which insurance plans cover Prometrium in Indiana?
Most commercial plans (Anthem, UnitedHealthcare, CareSource) cover generic micronized progesterone at Tier 1 or Tier 2 copays ($10-$30). Indiana Medicaid does not cover it for HRT. Medicare Part D plans vary but generally include generic coverage.
What's the cheapest way to get Prometrium in Indiana?
The cheapest legal option is compounded micronized progesterone at approximately $25 per month from a licensed 503A pharmacy. For FDA-approved generics, discount cards bring prices to $30-$38 at most Indiana retail pharmacies.
Are there Indiana Prometrium discount programs?
AbbVie offers a manufacturer copay savings card for brand Prometrium (commercial insurance required). GoodRx and RxSaver coupons reduce generic pricing to $30-$38. AbbVie also has a patient assistance program for uninsured patients below 200% FPL.
How does the AbbVie savings card work in Indiana?
The AbbVie copay card reduces brand Prometrium out-of-pocket costs to as low as $25 per fill for commercially insured patients. It does not apply to Medicare, Medicaid, or Tricare beneficiaries. Annual maximum benefit is typically $3,600. Re-enrollment required yearly.

References

  1. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs (Prometrium). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
  2. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7837245/
  3. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/17333341/
  4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
  5. Endocrine Society. Hormone Therapy in Primary Ovarian Insufficiency. J Clin Endocrinol Metab. 2022;107(10):2729-2747. https://academic.oup.com/jcem/article/107/10/2729/6639638
  6. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers